Take a read of the attached article and the below content, what might this mean for SPL DEP Remdersvir (rebranded Veklury)? If you were JF might a phone call to remind them of results go amiss??
Gilead hopes that the inhaled formulation of Veklury could increase its earnings on the drug, especially if the indication is expanded to non-hospitalized patients. The inhaled formulation could be used after patients have been infected but before hospitalization is needed. Currently, inhaled remdesivir is drudging along in a Phase I trial and still needs further testing before it can receive approval or emergency authorization.
